Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B2 measurement

Nicole Dodge Zantek; Russell V. Luepker; Sue Duval; Karen Miller; Niki Oldenburg; Alan T. Hirsch

doi:10.1177/1076029613486537

Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B₂ measurement

Nicole Dodge Zantek, Russell V. Luepker, Sue Duval, Karen Miller, Niki Oldenburg, Alan T. Hirsch

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B₂ (STxB₂) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB₂ measurement (Thromboxane B ₂ EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB ₂ levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB ₂ levels. A STxB₂ cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB₂ was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.

Original language	English (US)
Pages (from-to)	385-392
Number of pages	8
Journal	Clinical and Applied Thrombosis/Hemostasis
Volume	20
Issue number	4
DOIs	https://doi.org/10.1177/1076029613486537
State	Published - May 2014

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this research study was provided by the Lillehei Heart Institute, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN.

Keywords

NSAID
aspirin
cardiovascular prevention
compliance
nonsteroidal anti-inflammatory drug

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1177/1076029613486537

OpenUrl availability

Full text

Cite this

@article{6860350ab01943449dd9688667650651,

title = "Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B2 measurement",

abstract = "Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.",

keywords = "NSAID, aspirin, cardiovascular prevention, compliance, nonsteroidal anti-inflammatory drug",

author = "Zantek, {Nicole Dodge} and Luepker, {Russell V.} and Sue Duval and Karen Miller and Niki Oldenburg and Hirsch, {Alan T.}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this research study was provided by the Lillehei Heart Institute, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN.",

year = "2014",

month = may,

doi = "10.1177/1076029613486537",

language = "English (US)",

volume = "20",

pages = "385--392",

journal = "Clinical and Applied Thrombosis/Hemostasis",

issn = "1076-0296",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Confirmation of reported aspirin use in community studies

T2 - Utility of serum thromboxane B2 measurement

AU - Zantek, Nicole Dodge

AU - Luepker, Russell V.

AU - Duval, Sue

AU - Miller, Karen

AU - Oldenburg, Niki

AU - Hirsch, Alan T.

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this research study was provided by the Lillehei Heart Institute, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN.

PY - 2014/5

Y1 - 2014/5

N2 - Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.

AB - Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B 2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA-) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB 2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT- 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA- INT+ 176 (75, 390), and ASA- INT- 271 (199, 366). The INT use did not cause a significant difference in STxB 2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.

KW - NSAID

KW - aspirin

KW - cardiovascular prevention

KW - compliance

KW - nonsteroidal anti-inflammatory drug

UR - http://www.scopus.com/inward/record.url?scp=84899028752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899028752&partnerID=8YFLogxK

U2 - 10.1177/1076029613486537

DO - 10.1177/1076029613486537

M3 - Article

C2 - 23653145

AN - SCOPUS:84899028752

SN - 1076-0296

VL - 20

SP - 385

EP - 392

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

IS - 4

ER -